Clinical meaning
Digoxin toxicity is a potentially fatal adverse drug reaction resulting from excessive accumulation of digoxin (a cardiac glycoside derived from the foxglove plant Digitalis purpurea) in the body, producing dangerous cardiac arrhythmias, severe gastrointestinal symptoms, and characteristic neurological manifestations. Digoxin remains a commonly prescribed medication for heart failure with reduced ejection fraction and for ventricular rate control in atrial fibrillation, but it has an extremely narrow therapeutic index (therapeutic range 0.5-2.0 ng/mL, with toxicity increasingly likely above 2.0 ng/mL), making toxicity a persistent clinical concern. The fundamental mechanism of digoxin at the cellular level involves inhibition of the Na+/K+-ATPase (sodium-potassium pump), a transmembrane enzyme present in virtually all human cells that actively transports three sodium ions out of the cell and two potassium ions into the cell with each cycle, using ATP hydrolysis as the energy source. Digoxin binds to the extracellular alpha subunit of the Na+/K+-ATPase and locks the pump in a phosphorylated state, preventing the conformational change necessary for potassium binding and transport. This inhibition has profound consequences in cardiomyocytes due to the intimate coupling between sodium, calcium, and potassium handling. When Na+/K+-ATPase is inhibited by digoxin, intracellular sodium concentration rises because sodium is no longer being efficiently pumped out. The elevated intracellular sodium reduces the electrochemical gradient that drives the sodium-calcium exchanger (NCX), a secondary active transporter that normally uses the sodium gradient to extrude one calcium ion from the cell in exchange for three sodium ions entering. With reduced sodium extrusion by the pump and diminished NCX activity, intracellular calcium accumulates. At therapeutic digoxin levels, this modest increase in intracellular calcium enhances the force of myocardial contraction (positive inotropy) by providing more calcium to bind troponin C and activate the actin-myosin cross-bridge cycling apparatus, producing the desired hemodynamic benefit in heart failure. However, in digoxin toxicity, the excessive inhibition of Na+/K+-ATPase causes dangerous intracellular calcium overload. The sarcoplasmic reticulum (SR) becomes saturated with calcium and begins to spontaneously release calcium during diastole through ryanodine receptors (RyR2), generating delayed afterdepolarizations (DADs). When DADs reach threshold, they trigger ectopic beats and life-threatening arrhythmias. The hallmark arrhythmia of digoxin toxicity is the combination of enhanced automaticity (from DADs) with impaired conduction (from direct effects on the AV node and from hyperkalemia). Digoxin toxicity enhances automaticity in atrial, junctional, and ventricular tissues while simultaneously slowing conduction through the AV node (vagomimetic effect) and the His-Purkinje system (direct Na+/K+-ATPase inhibition in conduction tissue). This combination produces the pathognomonic arrhythmia of digoxin toxicity: bidirectional ventricular tachycardia, where the QRS axis alternates between two directions beat-to-beat, reflecting alternating foci of triggered activity in the right and left bundle branches. Other characteristic arrhythmias include atrial tachycardia with AV block (enhanced atrial automaticity combined with AV nodal conduction delay), accelerated junctional rhythm (enhanced junctional automaticity), and regularization of the ventricular response in atrial fibrillation (which normally has an irregularly irregular rhythm -- regularization indicates complete AV block with a junctional escape rhythm). Acute digoxin toxicity (massive single ingestion, often intentional) presents differently from chronic digoxin toxicity (gradual accumulation over days to weeks, often in elderly patients with declining renal function). Acute toxicity produces severe hyperkalemia because Na+/K+-ATPase inhibition in all cells reduces potassium uptake from the extracellular space, and the hyperkalemia itself exacerbates cardiac toxicity and may cause fatal ventricular fibrillation. Chronic toxicity more commonly presents with insidious GI symptoms (anorexia, nausea, vomiting), neurological symptoms (confusion, visual disturbances including xanthopsia -- a characteristic yellow-green visual discoloration -- and halos around lights), and cardiac arrhythmias. Chronic toxicity is often precipitated by factors that increase digoxin levels or enhance its effects: renal impairment (digoxin is 70% renally excreted), hypokalemia (reduced extracellular potassium increases digoxin binding to Na+/K+-ATPase), hypomagnesemia (magnifies electrophysiological toxicity), hypercalcemia (synergistic calcium overload), hypothyroidism (decreased digoxin clearance), advanced age, low body weight, and drug interactions (amiodarone, verapamil, quinidine, and macrolide antibiotics all raise digoxin levels by inhibiting P-glycoprotein-mediated renal secretion or displacing digoxin from tissue binding sites).